Article,
Evaluation of the Effectiveness of Liver Enzymes for Patients with Beta Thalassemia in Baghdad City Taking Iron Chelation Drugs Deferoxamine and Deferosirox
CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCE, 4 (1): 302-307 (January 2023)
Abstract
The study was conducted for the period from September 2022 to January 2023, and samples were collected in the city of Baghdad at the Genetic Blood Diseases Center of Ibn Al-Baladi Hospital for Children on the Rusafa side, the Hereditary Blood Diseases Center of Al-Karama Teaching Hospital on the Karkh side, and private clinics for hematologists in Baghdad. And blood samples were drawn from 70 patients with thalassemia major who were treated with regular blood transfusions and iron-chelating treatments Deferoxamine (DFO) and Deferasirox (DFX), where they were divided into two groups, each group 35 patients according to the type of treatment, and the control group (healthy) numbered 30 and in each group Three age groups, the first age group G1 / 5-10 years, the second age group G2 / 11-20 years, and the third age group G3 / 21-30 years All biochemical tests were performed, including liver enzymes Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) and the concentration of iron and ferritin. The results of the current study are explained. There was a significant increase (P≤0.05) for liver enzymes in ALT and AST for the two groups of beta thalassemia patients, and the deferoxamine group was higher, which was taken subcutaneously. AST enzyme was elevated for all age groups in the DFO group, while ALT enzyme was elevated in the first age group compared to the same group
